State Street Corp Buys 28,666 Shares of Medpace Holdings, Inc. $MEDP

Key Points

• State Street increased its Medpace stake by 4.2% in the second quarter, adding 28,666 shares to hold 710,895 shares worth approximately $376.5 million, or 2.55% of the company. Institutional investors collectively own 77.98% of MEDP.
• Medpace exceeded quarterly expectations, reporting $4.25 EPS versus the $3.98 consensus and revenue of $707.33 million, up 17.2% year over year. The company issued fiscal 2026 EPS guidance of $17.25–$17.95.
• Analysts maintain a largely cautious view, with three Buy ratings and nine Holds and an average price target of $595.20. Meanwhile, insiders sold roughly $148.7 million of stock over the past 90 days, including significant sales by the CEO and a director.

State Street Corp increased its stake in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 4.2% in the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 710,895 shares of the company's stock after acquiring an additional 28,666 shares during the period. State Street Corp owned about 2.55% of Medpace worth $376,483,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in MEDP. The Manufacturers Life Insurance Company raised its holdings in shares of Medpace by 38.9% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 20,043 shares of the company's stock valued at $10,615,000 after buying an additional 5,610 shares in the last quarter. Sequoia Financial Advisors LLC grew its position in Medpace by 8.2% during the second quarter. Sequoia Financial Advisors LLC now owns 1,108 shares of the company's stock valued at $587,000 after acquiring an additional 84 shares during the last quarter. Tidal Investments LLC grew its position in Medpace by 8.0% during the second quarter. Tidal Investments LLC now owns 6,155 shares of the company's stock valued at $3,260,000 after acquiring an additional 458 shares during the last quarter. Archford Capital Strategies LLC raised its stake in shares of Medpace by 5.4% during the second quarter. Archford Capital Strategies LLC now owns 1,658 shares of the company's stock worth $878,000 after acquiring an additional 85 shares in the last quarter. Finally, NewEdge Advisors LLC lifted its holdings in shares of Medpace by 3.9% in the 2nd quarter. NewEdge Advisors LLC now owns 2,865 shares of the company's stock worth $1,517,000 after acquiring an additional 108 shares during the last quarter. Institutional investors own 77.98% of the company's stock.

Medpace Trading Down 2.1%

Medpace stock opened at $617.15 on Thursday. The firm has a 50-day moving average of $591.38 and a 200-day moving average of $514.21. The firm has a market cap of $17.22 billion, a P/E ratio of 36.18, a P/E/G ratio of 2.81 and a beta of 1.15. Medpace Holdings, Inc. has a 1-year low of $373.00 and a 1-year high of $677.90.

Medpace (NASDAQ:MEDP - Get Free Report) last announced its quarterly earnings results on Wednesday, July 22nd. The company reported $4.25 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.98 by $0.27. The company had revenue of $707.33 million for the quarter, compared to the consensus estimate of $689.51 million. Medpace had a return on equity of 110.15% and a net margin of 17.67%.Medpace's revenue was up 17.2% compared to the same quarter last year. During the same quarter in the previous year, the business earned $3.10 EPS. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. Research analysts forecast that Medpace Holdings, Inc. will post 17.54 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on MEDP. Jefferies Financial Group reiterated a "hold" rating on shares of Medpace in a research report on Monday, September 14th. Royal Bank Of Canada lifted their price objective on Medpace from $484.00 to $692.00 and gave the stock an "outperform" rating in a report on Friday, July 24th. BMO Capital Markets boosted their target price on Medpace from $400.00 to $600.00 and gave the company a "market perform" rating in a research note on Friday, July 24th. Weiss Ratings upgraded Medpace from a "hold (c+)" rating to a "buy (b-)" rating in a report on Wednesday, August 12th. Finally, Robert W. Baird lifted their price target on Medpace from $547.00 to $624.00 and gave the stock a "neutral" rating in a research note on Friday, July 24th. Three research analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Hold" and an average price target of $595.20.

Insiders Place Their Bets

In other Medpace news, CEO August Troendle sold 49,018 shares of the company's stock in a transaction on Tuesday, September 22nd. The shares were sold at an average price of $628.11, for a total value of $30,788,695.98. Following the completion of the transaction, the chief executive officer directly owned 433,372 shares in the company, valued at approximately $272,205,286.92. This represents a 10.16% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Robert Kraft sold 3,858 shares of the firm's stock in a transaction dated Wednesday, August 26th. The stock was sold at an average price of $617.81, for a total transaction of $2,383,510.98. Following the completion of the sale, the director directly owned 955 shares of the company's stock, valued at approximately $590,008.55. This represents a 80.16% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 240,993 shares of company stock valued at $148,693,563 in the last ninety days. 20.50% of the stock is currently owned by insiders.

About Medpace

Medpace Holdings, Inc is a global contract research organization (CRO) that provides outsourced clinical development services to pharmaceutical, biotechnology and medical device companies. The company supports sponsors throughout the drug and medical product development process, from early-stage planning and clinical trial design through study execution, regulatory submission and post-marketing activities.

Its services include clinical trial management, clinical monitoring, data management, biostatistics, medical writing, pharmacovigilance, regulatory consulting and central laboratory services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.